We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out). More info.

Confirm

Discover Grünenthal

3/4/2013

Aachen, 4th March 2013 – Today, the Grünenthal Group announced the appointment of Yugo Takahashi to assume the position of General Manager, Grunenthal Farmaceutica do Brasil, effective February 27th, 2013. Yugo Takahashi will be based in São Paulo and will report directly to Oscar Ferenczi, Executive Vice President Latin America of the Grünenthal Group.

“With the acquisition of Selfarma in 2011 we laid the foundation for our market entry in Brazil. Having Yugo Takahashi on board will allow us to shape and implement the appropriate strategies to further penetrate and consolidate Grünenthal’s position in the Brazilian market”, commented Oscar Ferenczi, Executive Vice President Latin America of the Grünenthal Group.

The Grünenthal Group has a long tradition and strong position in many Latin American markets, and in particular Brazil is one of the most important strategic markets for Grünenthal in this region. “I am looking forward to my new position at Grünenthal. The pharmaceutical sector in Brazil is in a unique position combining current and future potential double digit growth while is already ranked 7th on the list of largest pharmaceutical markets worldwide. Based on Grünenthal’s excellent position in the entire Latin American market and the solid footprint in Brazil we will further expand the business here”, described Yugo Takahashi, General Manager of Grunenthal Farmaceutica do Brasil.


About Grünenthal

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation.

Grünenthal is one of the last five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. Research and development costs amounted to about 26 percent of revenues in 2012. Grünenthal’s research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.

Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries. Today, approx. 4,400 employees are working for the Grünenthal Group worldwide. In 2012, Grünenthal achieved revenues of €973 mn.


More information:
www.grunenthal.com.
 

Frank Schönrock

Vice President Public Engagement

Grünenthal GmbH


Aachen

E-Mail Frank.Schoenrock@grunenthal.com

Phone +49 241 569-1568